TACTILE SYSTEMS TECHNOLOGY INC

TCMD

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 565,642Value: $16.4M

# Signal Note: Driehaus Initiates TCMD Position Driehaus Capital's $16.4M entry into TCMD suggests conviction in the lymphedema care market, where the company's Flexitouch system maintains category leadership with recurring revenue through consumables. The position timing may reflect confidence in reimbursement stability or upcoming data/commercial catalysts, though TCMD faces competitive pressures from lower-cost alternatives and has shown modest revenue growth recently. Given Driehaus's biotech focus, this appears more of a medical device/recurring revenue play than a typical growth biotech bet.

More TCMD Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: